5 Biotech Stocks to Bet On Bright Industry Prospects

The second-quarter earnings season has kickstarted but only a handful of biotech companies have reported so far. The current outlook is encouraging, driven by new drug approvals and positive pipeline updates in the first half. Increasing R&D spending on lucrative areas of obesity and rare diseases, among others, is a positive as well.Companies in this volatile biotech industry continue to be in the spotlight as pharma/biotech goliaths are looking to bolster their product portfolios and pipelines through col ...